Background Inflammatory bowel diseases (IBDs) are characterised by dysbiosis and a leaky gut. The NADPH oxidase dual oxidase 2 (DUOX2) is upregulated in patients with IBD, yet its role in driving the ...

Veeco’s stock price closed at $28.46. It is down -2.63% in the last 3 months and up 29.95% in the last 12 months. Veeco saw 0 positive EPS revisions and 4 negative EPS revisions in the last 90 days.

Investing.com - Needham reiterated a Hold rating on Veeco Instruments Inc. (NASDAQ:VECO) Thursday. The firm noted Veeco reported fourth-quarter 2025 results in line with expectations, with ...

Veeco forecasts Q1 2026 revenue between $150 million and $170 million and gross margin between 37% and 38%. Full year 2026 revenue is forecasted between $740 million and $800 million, with gross ...

It is now my pleasure to introduce your host, Alex Delacroix, Head of Investor Relations. Thank you. You may begin. Thank you, and good afternoon, everyone. Joining me on the call today are Bill ...

Veeco Instruments Inc. reports fourth-quarter results after the market close Wednesday, closing out a tumultuous year marked by a pending merger with Axcelis Technologies and a strategic pivot toward ...

Veeco Instruments reported mixed financial results for Q4 2025, with revenue reaching $165 million, aligning with management guidance but showing no growth from the previous quarter. The company ...

(RTTNews) - Veeco Instruments (VECO) reported earnings for fourth quarter that Drops, from the same period last year The company's bottom line came in at $1.11 million, or $0.02 per share. This ...

PLAINVIEW, N.Y. (AP) — PLAINVIEW, N.Y. (AP) — Veeco Instruments Inc. (VECO) on Wednesday reported earnings of $1.1 million in its fourth quarter. On a per-share basis, the Plainview, New York-based ...